Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices 60471 

research, advocacy, and clinical practice 

communities, those employed by NIH or 

at institutions receiving NIH support, 

and the public, on a proposed revised 

mission statement. The bolded language 

reflects differences between the current 

and proposed mission statements. 

• Current mission statement: ‘‘To 

seek fundamental knowledge about the 

nature and behavior of living systems 

and the application of that knowledge to 

enhance health, lengthen life, and 

reduce illness and disability.’’ 

• Proposed revised mission 

statement: ‘‘To seek fundamental 

knowledge about the nature and 

behavior of living systems and to apply 

that knowledge to optimize health and 

prevent or reduce illness for all people.’’ 

Input sought about the proposed 

revised mission statement includes, but 

is not limited to, the following: 

• Feedback on whether the proposed 

new mission statement reflects the goals 

and objectives as outlined in the NIHWide Strategic Plan for Fiscal Years 

2021–2025 (https://www.nih.gov/sites/ 

default/files/about-nih/strategic-planfy2021-2025-508.pdf). 

• Suggestions for specific language 

that could be added to the proposed 

mission statement and why. 

• Feedback on any specific language 

that could be removed from the 

proposed mission statement and why. 

NIH encourages organizations (e.g., 

patient advocacy groups, professional 

societies) to submit a single response 

reflective of the views of the 

organization or its membership. 

Dated: August 29, 2023. 

Tara A. Schwetz, 

Acting Principal Deputy Director, National 

Institutes of Health. 

[FR Doc. 2023–18989 Filed 8–31–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Fiscal Year (FY) 2023 Notice of 

Supplemental Funding Opportunity 

AGENCY: Substance Abuse and Mental 

Health Services Administration, 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of intent to award 

supplemental funding. 

SUMMARY: This notice is to inform the 

public that the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) is supporting supplemental 

funding in the scope of the parent award 

to the 36 Rural Emergency Medical 

Services Training Grant (REMS) 

recipients funded under Notice of 

Funding Opportunity (NOFO) TI–23– 

011. These recipients have a project end 

date of September 29, 2024. The 

supplemental funding is to provide the 

opioid antagonist medication, naloxone, 

that can be used to treat respiratory 

depression in suspected opioid 

overdose patients, and for the 

procurement of emergency equipment 

used to rapidly reverse the effects of 

opioid overdoses. Recipients may 

receive up to $49,000 for the purchase 

of naloxone and up to $49,000 for 

purchasing equipment, for a total of 

$98,000 per recipient. 

FOR FURTHER INFORMATION CONTACT: 

Humberto Carvalho, Email: 

Humberto.Carvalho@samhsa.hhs.gov, 

Phone: (240) 276–2974. 

SUPPLEMENTARY INFORMATION: 

Funding Opportunity Title: Rural 

Emergency Medical Services Training 

TI–23–011. 

Assistance Listing Number: 93.243. 

Authority: The REMS Training grants 

are authorized under Section 330J of the 

Public Health Service Act, as amended 

(42 U.S.C. 254c15). 

Justification: This is not a formal 

request for application. Assistance will 

only be provided to the 36 REMS 

recipients funded in FY 2023 funded 

under Rural Emergency Medical 

Services Training Grant Funding 

Opportunity TI–23–011, based on the 

receipt of a satisfactory application and 

associated budget. The purpose of the 

supplement is to further expand and 

enhance REMS grant activities; 

therefore, only current recipients are 

eligible. 

Dated: August 28, 2023. 

Ann Ferrero, 

Public Health Analyst. 

[FR Doc. 2023–18911 Filed 8–31–23; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Donovan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Donovan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: In 

accordance with section 9.19 of the 

Mandatory Guidelines, a notice listing 

all currently HHS-certified laboratories 

and IITFs is published in the Federal 

Register during the first week of each 

month. If any laboratory or IITF 

certification is suspended or revoked, 

the laboratory or IITF will be omitted 

from subsequent lists until such time as 

it is restored to full certification under 

the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 


lotter on DSK11XQN23PROD with NOTICES1